Dermatomyositis (DM) is generally a disease with an increased risk of developing neoplasia, hence the need for regular monitoring. Researchers from two US centres studied two cohorts of DM and compared them to other immune system diseases and healthy subjects:
- anti-CCAR1 autoantibody was exclusively detected in the serum of DM patients positive for anti-TIF1-gamma antibody
- among the latter, the presence of this autoantibody was associated with a lower frequency of cancers over a period of at least three years.
The discovery of this biomarker will thus make it possible to better individualise the follow-up of DM patients.